<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02890745</url>
  </required_header>
  <id_info>
    <org_study_id>2016-100</org_study_id>
    <nct_id>NCT02890745</nct_id>
  </id_info>
  <brief_title>The Effect Effect of Empagliflozin on Oxidative Stress in Patients With Type 2 Diabetes</brief_title>
  <acronym>EMPOX</acronym>
  <official_title>EMPOX - A Randomised, Double-blinded, Placebo Controlled Study That Evaluates the Effect of Empagliflozin on Oxidative Stress in Patients With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Henrik Enghusen Poulsen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital, Gentofte, Copenhagen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the effect of empagliflozin on oxidative stress
      in patients with type 2 diabetes. The association is examined by comparing the difference in
      oxidative modifications before and after 14 days treatment with 25 mg empagliflozin compared
      to placebo treatment. The study is randomised, double-blinded, and placebo controlled. Each
      treatment group consists of 17 males with type 2 diabetes. Oxidative modifications are
      measured by urinary excretion of 8-oxo-7,8-dihydro-2'-deoxyguanosine and
      8-oxo-7,8-dihydroguanosine. A student t-test will be performed to compare the drug treatment
      with placebo. The results will be published in a peer-review journal.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2016</start_date>
  <primary_completion_date type="Anticipated">May 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Urinary excretion of 8-oxo-7,8-dihydro-2'-deoxyguanosine (nmol/24h)</measure>
    <time_frame>Change from baseline after fourteen days of intervention</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Urinary excretion of 8-oxo-7,8-dihydroguanosine (nmol/24h)</measure>
    <time_frame>Change from baseline after fourteen days of intervention</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma levels of malondialdehyde</measure>
    <time_frame>Change from baseline after fourteen days of intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma levels of iron, ferritin, transferrin and transferrin saturation</measure>
    <time_frame>Measured at baseline and after intervention</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">34</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Empagliflozin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One tablet 25 mg empagliflozin every morning for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One tablet placebo every morning for 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin</intervention_name>
    <arm_group_label>Empagliflozin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed with type 2 diabetes

          -  HbA1c: 6.5-9.0%

          -  Capable of understanding oral- and written information

        Exclusion Criteria:

          -  Estimated glomerular filtration rate (eGFR) &lt; 60 mL/hour/1.73 m2

          -  Currently receiving insulin treatment

          -  Coronary artery bypass grafting, percutaneous coronary intervention, acute coronary
             syndrome, stroke, lung embolism, deep vein thrombosis, or transitory cerebral ischemia
             within 6 months

          -  Genital infection within 14 days

          -  Plasma alanine aminotransferase ≥3 times upper normal limit

          -  Treatment with sodium glucose cotransporter (SGLT) -2 inhibitor within 2 months

          -  Hyperglycaemic symptoms

          -  Psychiatric disorder

          -  Intolerance to empagliflozin or other agents relevant to study

          -  Non-compliant
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Henrik Enghusen Poulsen, Professor, DMSc</last_name>
    <phone>+45 3545 7695</phone>
    <email>hepo@rh.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Center for Diabetes Research, Gentofte Hospital</name>
      <address>
        <city>Hellerup</city>
        <zip>2900</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jørgen Rungby, DMSc</last_name>
      <phone>+45 3977 7539</phone>
      <email>jr@biomed.au.dk</email>
    </contact>
    <investigator>
      <last_name>Jørgen Rungby, Professor, DMSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 31, 2016</study_first_submitted>
  <study_first_submitted_qc>August 31, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 7, 2016</study_first_posted>
  <last_update_submitted>December 1, 2016</last_update_submitted>
  <last_update_submitted_qc>December 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Henrik Enghusen Poulsen</investigator_full_name>
    <investigator_title>Professor, DMSc, chief physician</investigator_title>
  </responsible_party>
  <keyword>Empagliflozin</keyword>
  <keyword>Oxidative stress</keyword>
  <keyword>Oxidative nucleic acid modifications</keyword>
  <keyword>8-oxo-7,8-dihydro-2'-deoxyguanosine</keyword>
  <keyword>8-oxo-7,8-dihydroguanosine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empagliflozin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

